polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride
GOLYTELY (polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride) by R-Pharm US is osmotic activity [moa]. First approved in 1984.
Drug data last refreshed 8h ago · AI intelligence enriched 11h ago
GOLYTELY is an oral osmotic laxative solution containing polyethylene glycol 3350 and electrolytes, approved in 1984 for bowel preparation prior to colonoscopy and other GI procedures. It works by creating an osmotic gradient that draws fluid into the bowel, promoting complete evacuation without systemic absorption. This is a mature, off-patent product in the standard bowel prep category.
This legacy product faces mature market competition and revenue decline; teams are typically small and focused on cost management and volume retention rather than growth.
Osmotic Activity
Osmotic Laxative
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparison of Clenpiq vs Golytely Bowel Preparation
Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely
Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation
Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy
Worked on GOLYTELY at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moGOLYTELY offers limited career growth opportunities as a mature, off-patent commodity product with minimal clinical development and declining commercial momentum. Roles focus primarily on sales execution, cost management, and compliance rather than strategic innovation or market expansion.